Study to Compare the Bioavailability of Extended Release Metformin HCl Tablet Versus Glucophage XR® Tablets in Healthy Human Volunteers Under Fasting Condition

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01089166
Recruitment Status : Completed
First Posted : March 18, 2010
Last Update Posted : June 22, 2010
Information provided by:
Torrent Pharmaceuticals Limited

Brief Summary:

Objective: To compare the bioavailability of Extended Release Metformin HCl Tablet(Test formulation, Torrent Pharmaceuticals Ltd.,India) versus Glucophage XR® Tablets ( Reference formulation, Bristol-Myers Squibb Company, USA) in Healthy Human Volunteers under fasting condition.

Study Design: An Open-Label, Randomised, 2-Period, 2-Treatment,Crossover Study under fasting condition.

Condition or disease Intervention/treatment Phase
Type 2 Diabetes Drug: Metformin Phase 1

Study Type : Interventional  (Clinical Trial)
Official Title: To Compare the Bioavailability of Extended Release Metformin HCl Tablet(Test Formulation, Torrent Pharmaceuticals Ltd.,India) Versus Glucophage XR® Tablets ( Reference Formulation, Bristol-Myers Squibb Company, USA) in Healthy Human Volunteers Under Fasting Condition

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Torrent's Metformin tablets 500 mg Drug: Metformin
Active Comparator: Glucophage XR® of Bristol- Myers Squibb Company, USA) Drug: Metformin

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   Male

Inclusion Criteria:

  • Subjects must meet all of the following criteria in order to be included in the study:

    1. Sex: male.
    2. Age: 18 - 45 years.
    3. Subject with BMI of 18-27 (inclusive both) kg/m2 with minimum of 50 kg weight.
    4. Healthy and willing to participate in the study.
    5. Subject willing to adhere to the protocol requirements and to provide written informed consent.
    6. Non-smokers or smoker who smokes less than 10 cigarettes a day.

Exclusion Criteria:

  • The subjects will be excluded from the study based on the following criteria:

    1. Clinically relevant abnormalities in the results of the laboratory screening evaluation.
    2. Clinically significant abnormal ECG or Chest X-ray.
    3. Systolic blood pressure less than 100 mm Hg or more than 140 mm Hg and diastolic blood pressure less than 60 mm Hg or more than 90 mm Hg.
    4. Pulse rate less than 50/minute or more than 100/minute.
    5. Oral temperature less than 95°F or more than 98.6°F.
    6. Respiratory rate less than 12/minute or more than 20/minute
    7. Addiction to alcohol or history of any drug abuse within the past 2 years.
    8. Recent History of kidney or liver dysfunction.
    9. History of allergy to the test drug or any drug chemically similar to the drug under investigation.
    10. Administration/ Intake of prescription or OTC medication for two weeks before the study.
    11. Patients suffering from any chronic illness such as arthritis, asthma etc.
    12. HIV, HCV, HBsAg positive Subjects.
    13. Opioids, tetra hydrocannabinoids, amphetamine, barbiturates, benzodiazepine, Cocaine positive Subjects based on urine test.
    14. Subjects suffering from any psychiatric (acute or chronic) illness requiring medications.
    15. Administration of any investigational products in the period 0 to 3 months before entry to the study.
    16. Intake of barbiturates or any enzyme-inducing drug in last three months.
    17. History of significant blood loss due to any reason, including blood donation in the past 12 weeks. The total blood loss in last 3 months including for this study will not exceed 350ml.
    18. History of any bleeding disorder.
    19. Existence of any surgical or medical condition, which, in the judgement of the Chief investigator and/or clinical investigator, might interfere with the absorption, distribution, metabolism or excretion of the drug or likely to compromise the safety of Subjects.
    20. Inability to communicate or co-operate due to language problem, poor mental development or impaired cerebral function.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01089166

Torrent Research Centre
Bhat, Gujarat, India, 382 428
Sponsors and Collaborators
Torrent Pharmaceuticals Limited
Principal Investigator: Jogesh mahajan, MBBS Torrent Pharma Ltd.

Additional Information: Identifier: NCT01089166     History of Changes
Other Study ID Numbers: PK-07- 016
First Posted: March 18, 2010    Key Record Dates
Last Update Posted: June 22, 2010
Last Verified: March 2010

Additional relevant MeSH terms:
Hypoglycemic Agents
Physiological Effects of Drugs